secwatch.observer — SEC 8-K summary
======================================

Issuer:     Whitehawk Therapeutics, Inc. (WHWK)
CIK:        0001422142
Form:       8-K/A
Filed at:   2025-03-31T23:59:59+00:00
Accession:  0001193125-25-068845
Event type: other_material
Sentiment:  neutral
Materiality: 0.80
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Whitehawk closes sale of Aadi Subsidiary for $102.4M; pro forma cash $131M; FY2024 pro forma loss $25.2M
--------------------------------------------------------------------------------

- Sale closed March 25, 2025; total cash proceeds of $102.4M after purchase-price adjustments.
- Pro forma balance sheet as of Dec 31, 2024 shows cash & equivalents of $131.1M.
- Estimated gain on sale of $93.2M recorded; pro forma FY2024 net loss improves to $25.2M from historical $63.7M.
- Aadi revenue ($26.0M) and operating expenses ($64.3M) removed from pro forma statement.
- Stockholder approval obtained February 28, 2025; company retains no FYARRO program revenue.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525068845/0001193125-25-068845-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1422142/000119312525068845/d924652d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-068845

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer